Table 3. Risk of breast cancer-specific death according to key tumour characteristics and BRCA2 mutation status (period of diagnosis 1935–2012), adjusteda.

	Non-carriers					BRCA2 mutation
Characteristic	Patients (n)	Deaths (n)	HR	95% CI	P-value	Patients (n)	Deaths (n)	HR	95% CI	P-value	P-value interactionb
Size											0.14
T1⩽20 mm	256	51	1			109	39	1
T2>20 mm to 50 mm	179	70	1.95	1.34–2.85	0.001	102	53	1.52	0.99–2.33	0.06
T3>50 mm	27	17	5.97	3.41–10.45	<0.001	20	16	3.48	1.92–6.32	<0.001
Nodal involvement											0.3
No	285	64	1			117	41	1
Yes	215	101	2.86	2.08–3.92	<0.001	146	92	2.23	1.53–3.26	<0.001
Detailed information (n)	425	111				220	98
0 positive nodes	285	64	1			117	41	1
1–3 positive nodes	98	28	1.92	1.21–3.03	0.005	53	26	1.79	1.08–2.96	0.02
4–9 positive nodes	28	13	3.04	1.66–5.56	<0.001	28	17	2.99	1.68–5.31	<0.001
⩾10 positive nodes	15	7	5.04	2.26–11.23	<0.001	22	14	3.31	1.76–6.23	<0.001
Grade											0.11
1	135	35	1			32	20	1
2	240	93	1.66	1.12–2.45	0.01	139	75	1.1	0.67–1.81	0.7
3	138	44	1.77	1.13–2.77	0.01	96	38	0.96	0.55–1.67	0.89
ER status											<0.001
Negative	150	58	1			64	24	1
Positive	353	112	0.71	0.51–0.97	0.03	198	107	1.94	1.22–3.07	0.005

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio.

^aModel including year of birth and year of diagnosis.

^bInteraction between BRCA2 mutation status and the relevant variable.